S. Harnor

发表

The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice

R. Maxwell, D. Newell, E. Haagensen, 2013, PloS one.

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

M. Noble, J. Endicott, S. Cook, 2019, European journal of medicinal chemistry.

Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge

David M. Smith, L. Agius, C. Cano, 2020, Diabetes, obesity & metabolism.

Advanced approaches of developing targeted covalent drugs.

Qingjie Zhao, Conghao Gai, C. Cano, 2022, RSC medicinal chemistry.

Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification.

P. Dargan, I. Hardcastle, C. Cano, 2018, Clinical chemistry.

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor

M. Noble, J. Endicott, S. Cook, 2022, Journal of medicinal chemistry.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2016, Journal of medicinal chemistry.

Concise syntheses of bridged morpholines

R. Griffin, B. Golding, P. Waddell, 2016 .

2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase

I. Hardcastle, R. Griffin, B. Golding, 2020, RSC medicinal chemistry.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure−Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substitued 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2017 .

Synthesis of 3′-deoxy-3′-fluorothymidine (FLT) 5′-O-glucuronide: a reference standard for imaging studies with [18F]FLT

R. Griffin, B. Golding, D. Newell, 2014 .

Photochemical synthesis of benz[h]isoquinolines

J. C. Barnes, F. Ferrari, Belinda M. Abbott, 2008 .

N. Gray, N. Stiefl, M. Waring, 2018 .

Targeting DNA-PK as a Therapeutic Approach in Oncology

S. Wedge, C. Cano, E. Willmore, 2018 .

Targeting DNA‐Dependent Protein Kinase for Cancer Therapy

C. Cano, S. Harnor, Alfie Brennan, 2017, ChemMedChem.

Inhibition of the DNA-Dependent Protein Kinase for Cancer Therapy

C. Cano, S. Harnor, Alfie Brennan, 2017 .

Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family

C. Cano, S. Harnor, James E. Pickles, 2017 .

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

M. Noble, J. Endicott, M. Waring, 2021, Journal of medicinal chemistry.

Structure-activity analysis of CJ-15,801 analogues that interact with Plasmodium falciparum pantothenate kinase and inhibit parasite proliferation.

C. Spry, K. Saliba, S. Gul, 2018, European journal of medicinal chemistry.

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

M. Noble, J. Endicott, G. Chessari, 2021, Journal of medicinal chemistry.

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines

M. Noble, J. Endicott, I. Hardcastle, 2016, Journal of medicinal chemistry.

Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy.

S. Wedge, Duncan C Miller, S. Harnor, 2023, Journal of medicinal chemistry.

Targeting DNA‐Dependent Protein Kinase for Cancer Therapy

S. Harnor, Alfie Brennan, Céline Cano, 2017, ChemMedChem.